Fusion protein comprising interleukin-2 and interleukin-33
The present application discloses a novel fusion peptide of IL-2 and IL-33 and its use. It comprises a biologically active domain of Interleukin-2 (IL-2) or a biologically active fragment or homolog thereof, and a biologically active domain of Interleukin-33 (IL-33) or a biologically active fragment or homolog thereof. The two portions can be linked by a linker sequence. The application discloses that combination therapies using IL-2 and IL-33 or a therapy using the IL233 fusion protein are effective in preventing or treating diseases and disorders such as autoimmune diseases and disorders, inflammation, etc. Depending on the subject's disease or disorder, the compositions of the invention are useful for preventing certain symptoms, treating the disease, and alleviating at least some of the symptoms.
1. A fusion protein comprising a biologically active domain of Interleukin-2 (IL-2) or a biologically active fragment thereof, wherein said domain binds with the IL-2 receptor, and a biologically active domain of Interleukin-33 (IL-33) or a biologically active fragment thereof, wherein said IL-33 domain binds with the IL-33 receptor, further wherein said IL-2 domain is linked to said IL-33 domain with a linker sequence.
2. The fusion protein of claim 1 , wherein said protein comprises the amino acid sequence of SEQ ID NO:2 or SEQ ID NO: 11.
3. The fusion protein of claim 1 , wherein said linker comprises the sequence of SEQ ID NO:5.
4. The fusion protein of claim 1 , wherein said IL-2 comprises the sequence of SEQ ID NO:6 or SEQ ID NO:8 and said IL-33 comprises the sequence of SEQ ID NO:7 or SEQ ID NO:9, or biologically active fragments thereof.
5. The fusion protein of claim 4 , wherein said fragment of IL-2 comprises the sequence of SEQ ID NO:3, and said fragment of IL-33 comprises the sequence of SEQ ID NO:4, or biologically active fragments thereof.
6. The fusion protein of claim 5 , wherein said IL-2 comprises of at least 95% identity with SEQ ID NO:3 and said IL-33 comprises at least 95% identity with SEQ ID NO:4.
7. The fusion protein of claim 1 , wherein said protein is a synthetic protein.
8. A pharmaceutical composition comprising the fusion peptide of claim 1 , a pharmaceutically-acceptable carrier, and optionally an additional therapeutic agent.